84 related articles for article (PubMed ID: 18322384)
1. Functional genomics dissects pathomechanisms in tauopathies: mitosis failure and unfolded protein response.
Götz J; David D; Hoerndli F; Ke YD; Schonrock N; Wiesner A; Fath T; Bokhari L; Lim YA; Deters N; Ittner LM
Neurodegener Dis; 2008; 5(3-4):179-81. PubMed ID: 18322384
[TBL] [Abstract][Full Text] [Related]
2. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
[TBL] [Abstract][Full Text] [Related]
3. Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry.
Hoerndli FJ; Pelech S; Papassotiropoulos A; Götz J
Eur J Neurosci; 2007 Jul; 26(1):60-72. PubMed ID: 17587323
[TBL] [Abstract][Full Text] [Related]
4. Active immunization trial in Abeta42-injected P301L tau transgenic mice.
Kulic L; Kurosinski P; Chen F; Tracy J; Mohajeri MH; Li H; Nitsch RM; Götz J
Neurobiol Dis; 2006 Apr; 22(1):50-6. PubMed ID: 16289870
[TBL] [Abstract][Full Text] [Related]
5. Modulation of tau pathology in tau transgenic models.
Brion JP; Ando K; Heraud C; Leroy K
Biochem Soc Trans; 2010 Aug; 38(4):996-1000. PubMed ID: 20658992
[TBL] [Abstract][Full Text] [Related]
6. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
7. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
Sorrentino G; Bonavita V
Neurol Sci; 2007 Apr; 28(2):63-71. PubMed ID: 17464468
[TBL] [Abstract][Full Text] [Related]
8. Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau.
Yanagi K; Tanaka T; Kato K; Sadik G; Morihara T; Kudo T; Takeda M
Psychogeriatrics; 2009 Dec; 9(4):157-66. PubMed ID: 20377816
[TBL] [Abstract][Full Text] [Related]
9. Dissecting toxicity of tau and beta-amyloid.
Götz J; Lim YA; Ke YD; Eckert A; Ittner LM
Neurodegener Dis; 2010; 7(1-3):10-2. PubMed ID: 20160450
[TBL] [Abstract][Full Text] [Related]
10. Interneuronal transfer of human tau between Lamprey central neurons in situ.
Kim W; Lee S; Jung C; Ahmed A; Lee G; Hall GF
J Alzheimers Dis; 2010; 19(2):647-64. PubMed ID: 20110609
[TBL] [Abstract][Full Text] [Related]
11. Variations in the neuropathology of familial Alzheimer's disease.
Shepherd C; McCann H; Halliday GM
Acta Neuropathol; 2009 Jul; 118(1):37-52. PubMed ID: 19306098
[TBL] [Abstract][Full Text] [Related]
12. Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation.
Schindowski K; Belarbi K; Bretteville A; Ando K; Buée L
Genes Brain Behav; 2008 Feb; 7 Suppl 1(1):92-100. PubMed ID: 18184373
[TBL] [Abstract][Full Text] [Related]
13. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
[TBL] [Abstract][Full Text] [Related]
14. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
[TBL] [Abstract][Full Text] [Related]
15. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
Zilka N; Korenova M; Novak M
Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406
[TBL] [Abstract][Full Text] [Related]
16. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
[TBL] [Abstract][Full Text] [Related]
17. Frontotemporal dementia with tau pathology.
Gasparini L; Terni B; Spillantini MG
Neurodegener Dis; 2007; 4(2-3):236-53. PubMed ID: 17596718
[TBL] [Abstract][Full Text] [Related]
18. Divergent phosphorylation pattern of tau in P301L tau transgenic mice.
Deters N; Ittner LM; Götz J
Eur J Neurosci; 2008 Jul; 28(1):137-47. PubMed ID: 18662339
[TBL] [Abstract][Full Text] [Related]
19. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42).
Qin Z; Sun Z; Huang J; Hu Y; Wu Z; Mei B
Neurosci Lett; 2008 Oct; 444(3):217-21. PubMed ID: 18760331
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
